Cocaine users characteristically display preferences for smaller immediate rewards over larger delayed rewards, and this delay discounting (DD) has been proposed as an endophenotype of cocaine addiction. Recent evidence suggests that the norepinephrine system and more specifically the α 2A -adrenergic receptor (ADRA2A) are impacted by chronic cocaine use while also being potentially involved in the neural mechanisms underlying DD. Hence, we investigated the effects of ADRA2A polymorphisms and ADRA2A mRNA expression levels on DD of cocaine users and stimulant-naïve controls. Two hundred and twenty-three participants (129 cocaine users and 94 stimulant-naïve healthy controls) completed a computerized DD paradigm and were genotyped for three single nucleotide polymorphisms (SNPs; rs1800544, rs521674 and rs602618) in the ADRA2A gene, while their peripheral ADRA2A mRNA expression was quantified in whole blood samples. The three SNPs were in near-perfect linkage disequilibrium. Accordingly, significant group*genotype interactions were found for all three ADRA2A variants revealing steeper DD in cocaine users (but not in controls) carrying the G-allele of SNP rs1800544, the T-allele of rs521674 and the C-allele of rs602618. Similarly, high ADRA2A mRNA expression levels were significantly associated with a reduced tendency to choose smaller more immediate rewards (over larger delayed rewards) in cocaine users but not in controls. As the relationship between DD and cocaine use was moderated by ADRA2A SNPs and by peripheral ADRA2A gene expression, we propose that the norepinephrine system is involved in DD deficits observed in cocaine using individuals. Consequently, pharmacological compounds targeting ADRA2As might be considered for the symptom-specific treatment of delay aversion in stimulant addiction.
INTRODUCTION
Maladaptive decision-making has been suggested as a core feature in stimulant addiction as cocaine users characteristically seek the instantaneous and brief reinforcement of the drug despite its negative future consequences (Koob 2009; MacKillop 2013; Hulka et al. 2014) . At the basis of this behavior lies an impulsive preference for smaller immediate rewards over larger delayed rewards coined as delay discounting (DD). Several studies provided evidence that cocaine users display higher discounting rates for future rewards compared with stimulant-naïve controls (Coffey et al. 2003; Kirby & Petry 2004; Heil et al. 2006; Bickel et al. 2011; Hulka et al. 2014) . In addition, stronger DD has not only been associated with higher levels of drug consumption and poor treatment response in cocaine users but also with general negative outcomes in financial, professional and health domains (Mischel et al. 2011; Moffitt et al. 2011; Washio et al. 2011; Brody et al. 2014) . However, despite the importance of DD in cocaine addiction, its molecular underpinnings remain unclear so far.
Evidence from human and animal studies suggests the involvement of the norepinephrine (NE) system and more specifically the α 2A -adrenergic receptor (ADRA2A) in impulsive decision-making in general and in DD in particular. Studies performed in rats and in humans revealed that the NE reuptake inhibitor atomoxetine improved performance and decreased premature responding in stop-signal reaction time tasks (as an example for motor impulsivity) (Robinson et al. 2008; Bari & Robbins 2013 ). An experiment in rhesus monkeys has shown that the ADRA2A agonist guanfacine selectively reduced the animals' preference to choose smaller more immediate rewards (over larger delayed rewards) without affecting their risk preference (Kim et al. 2012) . While the presynaptic function of the ADRA2A is to inhibit NE transmitter release (suppression of NE release by negative feedback), it is also the most prevalent postsynaptic NE receptor in the prefrontal cortex (Arnsten et al. 1996) . Thus, it has been proposed that an activation of ADRA2As in the prefrontal cortex might be the mechanism by which guanfacine decreases DD (Kim et al. 2012) . Moreover, several genetic studies support an association of the G-allele of the ADRA2A C-1291G (rs1800544) single nucleotide polymorphism (SNP) with attention-deficit hyperactivity disorder (ADHD) (Park et al. 2005; Roman et al. 2006; Schmitz et al. 2006) . Accordingly, ADHD has also been associated with a preference to choose immediate over delayed rewards (Noreika et al. 2013) as well as with an increased vulnerability for addictive disorders (Urcelay & Dalley 2012) . Moreover, the G-allele of the ADRA2A rs1800544 SNP has been associated with higher vascular reactivity to cold and psychosocial stress corroborating the functional relevance of this SNP (Kelsey et al. 2012) .
Acute cocaine administration affects the NE system by inhibiting NE reuptake at the respective transporters and thus increasing synaptic NE signaling (Levy & Blattberg 1978; Clark et al. 1991; Fitzgerald 2013; O'Neill et al. 2013) . However, it is less clear how chronic cocaine use affects NE signaling. Recent evidence suggests that chronic use modifies the NE system by mechanisms involving ADRA2As (Fitzgerald 2013) . For example, rats exposed to 7 days of cocaine injections displayed permanent desensitization of ADRA2As (measured by a blunted growth hormone response to clonidine challenges) (Baumann et al. 2004) . Furthermore, the aforementioned ADRA2A agonist guanfacine has been associated with lower cocaine craving, anxiety and arousal in patients recovering from cocaine dependence, whereas the ADRA2A antagonist yohimbine facilitated reinstatement of cocaine seeking during early withdrawal in rats (Buffalari et al. 2012; Fox et al. 2012) .
Taken together, the NE system and in particular the ADRA2A are implicated in both DD and in the neurochemical adaptations after chronic cocaine consumption. Thus, our goal was to investigate whether three ADRA2A SNPs are associated with DD in chronic cocaine users compared with stimulant-naïve healthy controls. In addition to the aforementioned rs1800544, we further examined ADRA2A rs521674 and rs602618, which have been shown to be in linkage disequilibrium (LD) with rs1800544 in European and Asian populations (Clarke et al. 2012; Li et al. 2012) . As specific radioligands for molecular imaging of the ADRA2A are still lacking, we determined ADRA2A mRNA expression levels in peripheral blood in order to clarify the functional significance of the investigated polymorphisms. We hypothesized that both the ADRA2A polymorphisms and the ADRA2A mRNA expression levels are associated with DD preferences in chronic cocaine users.
MATERIALS AND METHODS

Participants
A total sample of 223 participants (129 chronic cocaine users and 94 stimulant-naïve controls) was investigated as part of the longitudinal Zurich Cocaine Cognition Study (ZuCo2St: Hulka et al. 2014; Preller et al. 2014; Vonmoos et al. 2013; Vonmoos et al. 2014) . Cocaine users were included if they indicated cocaine as their primary drug of choice, showed a use of >0.5 g/month and a maximum abstinence duration not longer than 6 months. Exclusion criteria for all participants were any current or previous neurological disorders or head injuries and use of prescription drugs affecting cognitive functioning. Additional exclusion criteria for the cocaine users were regular use of opioids or a polytoxic drug use pattern according to DSM-IV as well as any current or previous Axis-I DSM-IV psychiatric disorders with exception of cocaine and alcohol abuse/dependence, a history of depression and ADHD. Specific exclusion criteria for the control group were regular drug use (lifetime > 15 occasions) with the exception of nicotine dependence and occasional cannabis use and any current or previous Axis-I DSM-IV psychiatric disorder (American Psychiatric Association 1994). A participant's self-reports regarding drug use were confirmed by toxicological analyses of urine and hair samples (Table S1 ). Our sample of 129 cocaine users consisted of 94 regular recreational users (72.8%) and 35 dependent users (27.1%) according to DSM-IV. More detailed information about our sample and about selection, recruitment and drug screening procedures has been presented in detail in our previous work (Vonmoos et al. 2013; Hulka et al. 2014; Preller et al. 2014) . The presented study has been carried out in accordance with the Declaration of Helsinki and was approved by the Cantonal Ethics Committee of Zurich. All participants provided written informed consent prior to the study and were financially compensated for their participation.
Procedure
All participants were examined by trained psychologists using a Structural Clinical Interview (SCID-I) (Wittchen et al. 1997) according to DSM-IV. Drug use was assessed by using a structured and standardized Interview for Psychotropic Drug Consumption (Quednow et al. 2004) . The pre-morbid verbal intelligence quotient (IQ) was measured by the Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B, multiple choice vocabulary intelligence test) (Lehrl 1999) . Because psychiatric comorbidities such as depression and ADHD are common among cocaine-using populations (Rounsaville 2004; Pérez de Los Cobos et al. 2011 ), we applied the ADHD Self-Rating Scale (ADHD-SR) (Rosler et al. 2004 ) and the Beck Depression Inventory (BDI) (Beck et al. 1961) . In the frame of a comprehensive neuropsychological test battery, participants completed a computerized version of a DD paradigm of the Kirby Monetary Choice Questionnaire (Kirby & Petry 2004) using hypothetical rewards and fixed choices and enabling the calculation of the discounting rate of delayed rewards according to the formula V = A/(1 + kD). Hereby, V is the present value of the delayed reward A at delay D, and k is a free parameter that determines the discounting rate (the larger the parameter k, the stronger the discounting of delayed rewards) (Mazur 1987) . In order to better illustrate comparisons between cocaine users and controls, the main parameter k was z-transformed (based on mean and standard deviation of the control group) and multiplied by À1 so that higher z-scores indicate lower levels of reward impulsivity (i.e. little discounting of delayed rewards).
Genotyping and mRNA quantification
The ADRA2A polymorphisms (rs1800544, rs521674 and rs602618) were determined as described in the Supporting Information. In order to compare G-allele carriers in rs1800544 with non-carriers, the rare GG genotype (8.8%) was pooled with the CG genotype resulting in two genotype groups: CC versus CG/GG. Similarly, the rare TT genotype (8.8%) of rs521674 was pooled with the AT genotype, and the rare CC genotype (9.2%) of rs602618 was pooled with the AC genotype, respectively, resulting in the two genotype groups: AA versus AT/TT and AA versus AC/CC. For the haplotype analysis (provided in the Supporting Information) of the three SNPs (rs1800544, rs521674 and rs602618) contrasting non-carrier versus carriers of minor alleles (CC-AA-AA versus CG/GG-AT/TT-AC/CC), 10 participants with rare allele combinations were excluded.
Total RNA was isolated from whole blood using the RNA isolation NucleoSpin RNA blood in combination with the NucleoSpin RNA/DNA buffer set according to the manufacturer's recommendation (Macherey-Nagel AG, Oersingen, Switzerland). Total RNA samples were spectrophotometrically scanned (NanoVue, GE Healthcare Life Sciences, Cleveland, OH, USA) to obtain the A260/A280 of >1.9 and concentration levels. Additionally, for RNA quality resulting with RNA integrity number values, all samples were measured on the automated electrophoresis system (Experion, BioRad Co., Hercules, CA, USA). Quantitative real-time reverse transcription-polymerase chain reaction (PCR) was conducted for ADRA2A and six additional reference genes (ACTB, GAPDH, ALAS1, RPL13A, PPIA and 18S ribosomal RNA) as described previously (Grunblatt et al. 2009 ). Total RNA (500ng) from each sample was reverse transcribed using iScript cDNA synthesis kit (BioRad Co., Hercules, CA, USA). Each amplification was performed in a total volume of 20 μl containing 5 μl QuantiTect SYBR Green PCR kit (Qiagen, Venlo, The Netherlands) and the specific primer mix (PrimerAssay, Qiagen). PCR conditions were run according to manufacturer's manual (Qiagen). A melting point analysis was conducted for each assay to confirm specificity of PCR products, and all PCR reactions were run in triplicates. The program LinRegPCR (www.hartfaalcentrum.nl) was used to determine the PCR efficiency. Gene expression and normalization analysis with the most stable reference genes were conducted using the QBASE plus software (Biogazelle, Zwijnaarde, Belgium) (Vandesompele et al. 2002) . The software detected that the reference gene RPL13A was least stable and therefore this gene was excluded and normalization analysis was conducted using the five other reference genes.
Statistical analyses
Gene effects on DD were analyzed separately for each SNP using analyses of covariance (ANCOVAs) with the factors group (twofold, cocaine users versus controls) and genotype (twofold, CC versus CG/GG) and the covariates age and verbal IQ. Another ANCOVA with the additional covariates BDI score, ADHD-SR score and cumulative cocaine dose was calculated to investigate possible influences of these additional factors. ADRA2A mRNA expression levels were stratified into high versus low mRNA expression using median split. DD was then investigated using ANCOVAs with the factors group (as mentioned previously) and mRNA expression levels (high versus low) and the covariates age and verbal IQ. Finally, post hoc t-tests were conducted on the basis of significant ANCOVA main effects where necessary. Results were considered significant if P < 0.05 after correction for multiple comparisons using the Hochberg method. Hochberg's procedure (a step-up modification of the Bonferroni method) tests each partition hypothesis using all the order statistics by formulating a sequence of critical values based on Simes' inequality (Hochberg 1988) . Statistical analyses were conducted with SPSS (version 20.0, SPSS Inc., Chicago, IL, USA); testing of LD between polymorphisms was performed with the software HAPLOVIEW (Barrett et al. 2005) , and associations between polymorphisms and cocaine use was analyzed with the Armitage's trend test.
RESULTS
Demography and association analysis
The comparison between cocaine users and controls did not reveal significant differences regarding age and sex distribution (Table 1) . However, cocaine users had significantly fewer years of education, lower IQ scores, higher scores in the BDI and higher ADHD-SR scores than controls. Beyond these group differences, one-way ANCOVAs with age and IQ as covariates showed no significant genotype (rs1800544) or group*genotype interaction effects on BDI [genotype: F (1, 215) = 0.40, P = 0.53; interaction: F(1, 215) = 0.03, P = 0.87] or ADHD-SR scores [genotype: F(1, 215) = 0.82, P = 0.37; interaction: F(1, 215) = 0.03, P = 0.85]. For information on the substance use of both groups, see Table S1 in the Supporting Information. Genotype frequencies of all three polymorphisms were distributed in accordance with the Hardy-Weinberg equilibrium (Table S2) , and all three SNPs were found to be in near-perfect LD with each other (rs1800544/rs521674: D′ = 1.0, LOD = 92.24, r 2 = 0.99; rs1800544/rs602618: D′ = 0.98, LOD = 79.62, r 2 = 0.92; rs521674/rs602618: D′ = 0.97, LOD = 77.66, r 2 = 0.91) (Fig. S1) . None of the polymorphisms was associated with cocaine use per se (Table S2) , and within the group of cocaine users, genotype groups did not differ regarding cocaine consumption (Table S3) .
ADRA2A polymorphisms and delay discounting
Results are reported for rs1800544; however, the same results have been found for the two other SNPs due to the strong linkage disequilibrium (Table S2 and Fig. S1 ).
As shown previously in a part of the present sample , cocaine users were more likely to choose immediate smaller rewards over larger delayed rewards as indicated by significant group effects on DD in small, medium and large reward magnitudes, respectively (Table 2 ). There was no significant main effect of the factor genotype, but a significant group*genotype interaction was found across all reward magnitudes (Fig. 1, Fig. S2 ). In contrast, controls showed the reverse pattern, but the post hoc test did not show a significant difference [t(90) = À1.45, P = .15, d = 0.33]. This interaction remained significant even when BDI score, ADHD-SR score and cumulative cocaine dose were introduced together as additional covariates [rs1800544: F(1, 211) = 8.93, P cor < 0.01, ηp 2 = 0.04,
Of the covariates' main effects, none was strong enough to survive multiple comparison correction (age: P cor = 0.06; verbal IQ: P cor = 0.57; BDI score: P cor = 0.10; ADHD-SR: P cor = 0.98; cumulative cocaine dose: P cor = 0.08). Analyses of the unpooled rs1800544 genotype (i.e. CC versus CG versus GG, see Table S4 and Fig. S3 ), and a haplotype analysis (CC-AA-AA versus CG/GG-AT/TT-AC/CC, see Table S5 and Fig. S4 ) revealed similar results.
ADRA2A mRNA expression and delay discounting
After mRNA quality control, 104 samples were eligible for the ADRA2A gene expression analysis. Peripheral mRNA expression did not differ between cocaine users (n = 54) and controls (n = 50) and between genotype groups (Table S6) . However, using a median split of the mRNA expression (high versus low) together with the factor group in a two-way ANCOVA revealed a significant group*mRNA expression interaction on mean DD across rewards [F(1, 98) = 5.22, P < 0.05, ηp 2 = 0.05, Cohen's f = 0.23, Fig. 2 ], mirroring the group*genotype interaction shown previously (Fig. 1) . The interaction was explained by more pronounced DD in cocaine users with low levels of ADRA2A mRNA expression compared with users with high levels, as indicated by a strong statistical trend and a considerable effect size in the post hoc test [t(52) = 1.83, P = 0.07, d = 0.50]. Again, controls showed the reverse pattern, which was not significant [t(48) = À1.53, P = 0.13, d = 0.43]. Importantly, within the cocaine user group, the period of abstinence of cocaine use (Table S1 ) was neither correlated with ADRA2A mRNA expression (Pearson's product moment correlation: r = À0.12, P = 0.36, n = 54) nor with DD (r = 0.05, P = 0.59, n = 129). Also, a positive urine test for cocaine (Table S1 ) did not affect ADRA2A mRNA expression level in cocaine users [negative: 1.33 +/À1.0 SD; positive 1.19 +/À0.8 SD; t(51) = 0.44, P = 0.66]. Moreover, we have previously shown in an overlapping sample that a cocaine-positive urine test does not affect DD . Accordingly, inclusion of abstinence duration or cocaine urine screening status as additional covariates in the analyses did not change our results.
DISCUSSION
Examining the molecular mechanisms of DD in cocaine users and healthy controls, we were able to demonstrate that three linked ADRA2A SNPs (rs1800544, rs521675 and rs602618) as well as peripheral ADRA2A mRNA expression levels mediate reward impulsivity in dependence of cocaine use of the participants. More specifically, we Figure 1 Mean delay discounting (DD) across reward magnitudes for rs1800544 with significant (P < 0.01) group*genotype interactions (mean and SE, z-transformed and corrected for age and verbal IQ). Higher scores depict decreased discounting, whereas lower scores show increased discounting. Significant post hoc t-test on genotype (CC versus CG-GG) in cocaine users: **P < 0.01 
Controls
Cocaine Users ( * ) Figure 2 Mean delay discounting (DD) across reward magnitudes in cocaine users and controls stratified for high versus low ADRA2A mRNA expression levels (mean and SE, z-transformed and corrected for age and verbal IQ). Higher scores depict decreased discounting, whereas lower scores show increased discounting. Near-significant post hoc t-test on genotype (CC versus CG-GG) in cocaine users: (*)P = 0.07
found that in cocaine users, the G-allele of rs1800544 (and the T-allele of rs521674, as well as the C-allele of rs602618) as well as low ADRA2A mRNA concentrations were associated with steeper discounting of delayed rewards, while there were no significant differences between genotypes in healthy controls. Interestingly, the current findings are in line with previous reports on the role of ADRA2A polymorphisms in ADHD, as the G-allele of rs1800544 has repeatedly been proposed as a risk allele for ADHD as well as for its symptoms of impulsive decision-making (Roman et al. 2003; Park et al. 2005; Stevenson et al. 2005; Roman et al. 2006; Schmitz et al. 2006; Gizer et al. 2009 ). However, a large meta-analysis found no consistent evidence for a relationship between the G-allele and ADHD but a significant heterogeneity of results from different studies (Gizer et al. 2009 ). Consequently, the authors suggested that future studies should explore potential moderators as explanation for this heterogeneity. Accordingly, a recent study on the relationship between ADRA2A SNPs (rs1800544, rs553668 and rs1800545) and ADHD found mediating effects of personality (namely, associations with novelty seeking, persistence and harm avoidance) (de Cerqueira et al. 2011) . In addition, another study presenting an association of rs1800544 with intra-individual variability in response time suggested that ADRA2A SNPs are rather associated with objectively measureable endophenotypes of ADHD (such as intraindividual variability in response time) than with the complete clinical phenotype of ADHD itself (Cummins et al. 2014) . In line with these two studies, we provide evidence for an interaction between ADRA2A SNPs and cocaine use regarding DD, which has been proposed as an addiction endophenotype (MacKillop 2013).
Beyond its association with ADHD symptoms, the G-allele of rs1800544 has been found to be related to alcohol dependence and tobacco smoking (Prestes et al. 2007; Karahalil et al. 2008) . In addition, it has been discovered that carrying the G-allele was associated with a higher consumption of sweets (such as chocolate, candies and nougat) in a study with children and adolescents (Maestu et al. 2007 ) and also with an elevated stress response to cold and psychosocial stressors in adolescents and young adults (Kelsey et al. 2012) . Finally, even though only few studies focused on the rs521674 and rs602618 polymorphisms, they have recently been associated with a positive family history of alcoholism (Clarke et al. 2012) . These findings support the view that the minor alleles of these SNPs might impact addictive behaviors given that the common denominator of alcohol and tobacco dependence, stimulant addiction and obesity is the propensity to favor immediate rewards at the expense of negative future consequence (Mazur 1987; MacKillop 2013 ). However, it should be noted that, beyond the shown group*genotype interaction on DD, we did not find an association between the investigated ADRA2A SNPs and cocaine use per se.
It is still uncertain whether the three investigated SNPs mapping to the promoter region of the ADRA2A gene have functional significance. However, theoretical transcription binding sites suggest that at least rs521674 and rs60218 create new transcription binding sites at the T and C polymorphisms, respectively (e.g. http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/ promoinit.cgi?dirDB=TF_8.3). Additionally, the mRNA quantification in our present study provides an additional source of information. We found that cocaine users with high peripheral ADRA2A mRNA expression levels showed normal DD, while cocaine users with low mRNA expression levels revealed a strong DD endophenotype even though this effect was only a statistical trend (P = 0.07) in the post hoc comparison (Fig. 2) . Notably, the sample size for the mRNA expression analysis was much lower than for the SNP analysis (only 104 participants were eligible for the mRNA expression analysis) because of our strict mRNA quality control, and, thus, the gene expression analysis was less well powered. However, post hoc power analyses revealed that group*genotype (f = 0.22) and group*gene expression (f = 0.23) interactions on DD displayed highly similar effect sizes. Moreover, also, the post hoc comparisons on DD in the cocaine group showed comparable effect sizes in the genotype (G versus CG/GG: d = 0.56) and gene expression analysis (high versus low: d = 0.50). With this, also, our mRNA findings corroborate that cocaine use moderates the effects of ADRA2A genotype on DD. Support for this assumption stems from two animal studies. On the one hand, chronic cocaine administration has been shown to desensitize or downregulate postsynaptic ADRA2As from 42 hours up to 8 days later in the rat brain (Baumann et al. 2004) . On the other hand, the ADRA2A agonist guanfacine was able to reduce impulsivity in rhesus monkeys by increasing the proportion of choices of larger delayed rewards over smaller immediate rewards (Kim et al. 2012) . Based on these two studies, we postulate that control individuals have unaffected ADRA2As, whereas in cocaine users, ADRA2As may have been desensitized or downregulated by chronic drug consumption. Under these circumstances, higher receptor mRNA expression may be capable of mimicking the beneficial effects of guanfacine resulting in normal DD.
In line with our findings, a recent review highlights the potential of guanfacine as a therapeutic agent to attenuate stress-induced and cue-induced craving in cocaine-dependent individuals (Fox & Sinha 2014) . The authors further propose that guanfacine may be an effective medication to reduce craving and relapse vulnerability in other forms of addiction as well, because of its ability to improve cognitive and emotional control over drug-seeking behavior (Fox & Sinha 2014) .
The present study has two limitations. First, because of the low frequency of the GG genotype of rs1800544 (8.8%) in combination with our limited sample size, we decided to contrast G-allele carriers against non-carriers. Even though the threefold genotype comparison (CC versus CG versus GG) revealed comparable results (Table  S4 and Fig. S1 ), we have chosen to rely on the two-group comparisons for our interpretations. Second, because of the cross-sectional analysis in this study, it is not possible to answer conclusively whether the ADRA2A genotype*cocaine use interaction on DD develops as a consequence of cocaine use or if DD together with ADRA2A SNPs predisposes cocaine addiction, as there is evidence for both interpretations (Brody et al. 2014) . Our recent longitudinal results suggest that-in contrast to self-reported impulsivity and decision-making in the Iowa Gambling Task-DD is largely stable in cocaine users and does not change with decreased or increased use supporting the view that DD might be a predisposition and a potential endophenotype of cocaine addiction (Hulka et al. 2015) . However, the sample size of our longitudinal study is too small to investigate potential genotype effects on the course of DD. Thus, to draw definite conclusions, future studies should use longitudinal designs with larger samples in order to investigate the causal relationships between DD, cocaine use and ADRA2A SNPs more in-depth.
In conclusion, we presented evidence that relationship between the DD endophenotype and cocaine use is moderated by three SNPs of the ADRA2A gene as well as by ADRA2A gene expression suggesting that the NE system is involved in DD observed in cocaine users. As DD deficits may underlie addictive disorders in general, our results suggest that pharmacological compounds targeting ADRA2A (such as guanfacine) might be considered as option for symptom-specific treatment of DD in stimulant addiction.
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Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Fig. S2 Mean delay discounting (DD) of small, medium, and large reward magnitudes for rs1800544 with significant (p<0.01) group*genotype interactions (mean and SE, z-transformed and corrected for age and verbal IQ). Higher scores depict decreased discounting, whereas lower scores show increased discounting. Significant post hoc t-tests on genotype (CC vs. CG-GG) in cocaine users: **p<.01 Fig. S3 Mean delay discounting scores across reward magnitudes (unpooled genotypes: CC vs. CG vs. GG) with significant group*genotype interactions (mean and SE, z-transformed and corrected for age and verbal IQ, one subject has been excluded). Higher scores depict decreased discounting, whereas lower scores show increased discounting Fig. S4 Mean delay discounting scores across reward magnitudes (haplotype analysis: CC-AA-AA vs. CG/ GG-AT/TT-AC/CC,) with significant group*genotype interactions (mean and SE, z-transformed and corrected for age and verbal IQ, ten participants with rare allele combinations were excluded). Higher scores depict decreased discounting, whereas lower scores show increased discounting. Significant post hoc t-test on genotype (CC vs. CG-GG) in cocaine users: **p<.01.
